Advances in Skin Cancer Diagnosis: Using New Technologies to Identify High-Risk Patients

Format: Webcourse

Credit(s): 1.00 (60 min)

Release Date: Jun 18, 2021

Expiration Date: Jun 18, 2022

Credit Type(s):

CME / AMA PRA Category 1 Credit™
Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

Despite advances in screening and treatment, skin cancer remains a major source of morbidity and mortality in the United States. Early detection and appropriate, risk-adjusted treatment is essential to ensure optimal patient outcomes. Unfortunately, diagnosis and staging of skin cancers like melanoma and cutaneous squamous cell carcinoma (cSCC) can be challenging. Determining the risk status of newly diagnosed patients is particularly important, as it has major implications for treatment selection. Failure to appropriately assess patient risk can lead to either over or undertreatment, negatively impacting patient outcomes. In recent years, novel technologies designed to aid in diagnosis, staging, risk assessment, and treatment decision-making have emerged for melanoma and cSCC, and many more are in development. Use of these tests can help dermatologists in early identification of patients with high-risk disease who may require a more aggressive treatment approach.

This activity, Advances in Skin Cancer Diagnosis: Using New Technologies to Identify High-Risk Patients will review emerging trends in diagnosis and risk stratification for patients with common skin cancers, including melanoma and cSCC, including discussion of current diagnostic strategies, challenges in risk stratification, and clinical applications for new molecular tests designed to identify high-risk patients and aid in treatment decision-making.